Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FPR1 | P21462 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12763774 | 0.89 | CA12 (0.45) | CA12CA1CA2CA9MLYCD | |
| SCHEMBL24061317 | 0.88 | CA12 (0.41) | CA12CA1CA2CA9MLYCD | |
| SCHEMBL27014703 | 0.87 | CA1 (0.43) | CA12CA1CA2CA9MLYCD | |
| SCHEMBL15359960 | 0.85 | CA12 (0.42) | CA12CA1CA2CA9MLYCD | |
| SCHEMBL12588890 | 0.83 | CA1 (0.48) | CA12CA1CA2CA9MLYCD | |
| SCHEMBL10257143 | 0.82 | KDM4C (0.40) | CA12CA1CA2CA9LMNA | |
| SCHEMBL6893955 | 0.79 | CA12 (0.45) | CA12CA1CA2CA9MLYCD | |
| SCHEMBL6894039 | 0.79 | CA12 (0.45) | CA12CA1CA2CA9MLYCD | |
| SCHEMBL11682685 | 0.78 | CA1 (0.38) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL306030 | 0.78 | CA1 (0.48) | CA12CA1CA2CA9MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687490-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-03-30 | — | — | US | claimed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | claimed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | claimed |
| WO-2020153433-A1 | SUBSTITUENT-INCLUDING UREA COMPOUND | 第一三共株式会社 | 2020-07-30 | — | — | WO | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| EP-2415875-B1 | METHOD FOR IDENTIFICATION OF METALLO-[BETA]-LACTAMASE-PRODUCING BACTERIUM | MEIJI SEIKA PHARMA CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8697382-B2 | Method of identifying metallo-β-lactamase-producing bacteria | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-04-15 | — | — | US | disclosed |
| US-8344154-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120064557-A1 | METHOD OF IDENTIFYING METALLO-BETA-LACTAMASE-PRODUCING BACTERIA | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| EP-2415875-A1 | METHOD FOR IDENTIFICATION OF METALLO- B -LACTAMASE-PRODUCING BACTERIUM | Meiji Seika Pharma Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| CN-1309699-C | Method and apparatus for preparing dialkyl carbonate | GEN ELECTRIC (US) | 2007-04-11 | — | — | CN | disclosed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| CN-1678559-A | Method and apparatus for preparing a dialkyl carbonate | GEN ELECTRIC (US) | 2005-10-05 | — | — | CN | disclosed |
| EP-1562889-A1 | METHOD AND APPARATUS FOR PREPARING A DIALKYL CARBONATE | GENERAL ELECTRIC COMPANY (a New York Corporation) (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1419132-A1 | METHOD FOR PREPARING A DIALKYL CARBONATE, AND ITS USE IN THE PREPARATION OF DIARYL CARBONATES AND POLYCARBONATES | GENERAL ELECTRIC COMPANY (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2004000780-A1 | METHOD AND APPARATUS FOR PREPARING A DIALKYL CARBONATE | GENERAL ELECTRIC COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003016258-A1 | METHOD FOR PREPARING A DIALKYL CARBONATE, AND ITS USE IN THE PREPARATION OF DIARYL CARBONATES AND POLYCARBONATES | GENERAL ELECTRIC COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | CA12 909/4885CA1 727/4885CA2 313/4885 |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | CA12 909/4885CA1 727/4885CA2 313/4885 |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, BPGM | CA12 799/4885CA1 3160/4885CA2 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.